These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

830 related articles for article (PubMed ID: 29066514)

  • 1. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8
    Canale FP; Ramello MC; Núñez N; Araujo Furlan CL; Bossio SN; Gorosito Serrán M; Tosello Boari J; Del Castillo A; Ledesma M; Sedlik C; Piaggio E; Gruppi A; Acosta Rodríguez EA; Montes CL
    Cancer Res; 2018 Jan; 78(1):115-128. PubMed ID: 29066514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-12 and IL-4 activate a CD39-dependent intrinsic peripheral tolerance mechanism in CD8(+) T cells.
    Noble A; Mehta H; Lovell A; Papaioannou E; Fairbanks L
    Eur J Immunol; 2016 Jun; 46(6):1438-48. PubMed ID: 26990545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating CD39
    Qi Y; Xia Y; Lin Z; Qu Y; Qi Y; Chen Y; Zhou Q; Zeng H; Wang J; Chang Y; Bai Q; Wang Y; Zhu Y; Xu L; Chen L; Kong Y; Zhang W; Dai B; Liu L; Guo J; Xu J
    Cancer Immunol Immunother; 2020 Aug; 69(8):1565-1576. PubMed ID: 32306075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant Expression of CD39, CD69, and CD103 Identifies Antitumor CD8
    Lama GIG; Noél G; Márquez FCL; Galarza FFG; Hinojosa AIP; Rivera LEN; Willard-Gallo K; Astorga JRA
    Curr Pharm Biotechnol; 2024; 25(13):1747-1757. PubMed ID: 37680154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness.
    Hilchey SP; Kobie JJ; Cochran MR; Secor-Socha S; Wang JC; Hyrien O; Burack WR; Mosmann TR; Quataert SA; Bernstein SH
    J Immunol; 2009 Nov; 183(10):6157-66. PubMed ID: 19864600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
    Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
    Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells.
    Martinez-Usatorre A; Carmona SJ; Godfroid C; Yacoub Maroun C; Labiano S; Romero P
    Front Immunol; 2020; 11():340. PubMed ID: 32174925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.
    Duhen T; Duhen R; Montler R; Moses J; Moudgil T; de Miranda NF; Goodall CP; Blair TC; Fox BA; McDermott JE; Chang SC; Grunkemeier G; Leidner R; Bell RB; Weinberg AD
    Nat Commun; 2018 Jul; 9(1):2724. PubMed ID: 30006565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD39
    Tallón de Lara P; Castañón H; Vermeer M; Núñez N; Silina K; Sobottka B; Urdinez J; Cecconi V; Yagita H; Movahedian Attar F; Hiltbrunner S; Glarner I; Moch H; Tugues S; Becher B; van den Broek M
    Nat Commun; 2021 Feb; 12(1):769. PubMed ID: 33536445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial dynamics of CD39
    Tanoue K; Ohmura H; Uehara K; Ito M; Yamaguchi K; Tsuchihashi K; Shinohara Y; Lu P; Tamura S; Shimokawa H; Isobe T; Ariyama H; Shibata Y; Tanaka R; Kusaba H; Esaki T; Mitsugi K; Kiyozawa D; Iwasaki T; Yamamoto H; Oda Y; Akashi K; Baba E
    Nat Commun; 2024 Oct; 15(1):9033. PubMed ID: 39426955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenosine Generated by Regulatory T Cells Induces CD8
    Shi L; Feng M; Du S; Wei X; Song H; Yixin X; Song J; Wenxian G
    Biomed Res Int; 2019; 2019():4093214. PubMed ID: 31930120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes.
    Parodi A; Battaglia F; Kalli F; Ferrera F; Conteduca G; Tardito S; Stringara S; Ivaldi F; Negrini S; Borgonovo G; Simonato A; Traverso P; Carmignani G; Fenoglio D; Filaci G
    Cancer Immunol Immunother; 2013 May; 62(5):851-62. PubMed ID: 23359087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.
    Zahran AM; Rayan A; Zahran ZAM; Mohamed WMY; Mohamed DO; Abdel-Rahim MH; El-Badawy O
    PLoS One; 2022; 17(1):e0262650. PubMed ID: 35051220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse PVRIG Has CD8
    Murter B; Pan X; Ophir E; Alteber Z; Azulay M; Sen R; Levy O; Dassa L; Vaknin I; Fridman-Kfir T; Salomon R; Ravet A; Tam A; Levin D; Vaknin Y; Tatirovsky E; Machlenkin A; Pardoll D; Ganguly S
    Cancer Immunol Res; 2019 Feb; 7(2):244-256. PubMed ID: 30659055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
    Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
    Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically driven CD39 expression shapes human tumor-infiltrating CD8
    Gallerano D; Ciminati S; Grimaldi A; Piconese S; Cammarata I; Focaccetti C; Pacella I; Accapezzato D; Lancellotti F; Sacco L; Caronna R; Melaiu O; Fruci D; D'Oria V; Manzi E; Sagnotta A; Parrino C; Coletta D; Peruzzi G; Terenzi V; Battisti A; Cassoni A; Fadda MT; Brozzetti S; Fazzi K; Grazi GL; Valentini V; Chirletti P; Polimeni A; Barnaba V; Timperi E
    Int J Cancer; 2020 Nov; 147(9):2597-2610. PubMed ID: 32483858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction.
    Witt M; Oliveira-Ferrer L; Koch-Nolte F; Menzel S; Hell L; Sturmheit T; Seubert E; Weimer P; Ding Y; Qi M; Schmalfeldt B; Bokemeyer C; Fiedler W; Wellbrock J; Brauneck F
    Oncoimmunology; 2024; 13(1):2346359. PubMed ID: 38737794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer.
    Bareche Y; Pommey S; Carneiro M; Buisseret L; Cousineau I; Thebault P; Chrobak P; Communal L; Allard D; Robson SC; Mes-Masson AM; Provencher D; Lapointe R; Stagg J
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39
    Leem G; Park J; Jeon M; Kim ES; Kim SW; Lee YJ; Choi SJ; Choi B; Park S; Ju YS; Jung I; Kim S; Shin EC; Lee JY; Park SH
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.